Metastatic Adenocarcinoma of Prostate posing as upper tract ureteral mass

Prostate cancer metastasis to the ureter is extremely rare because only 45 such cases have been reported worldwide in the last century. It accounts for 30% of ureteral metastasis. Neuroendocrine differentiation is approximately 1% of the entire primary prostate adenocarcinoma pathology. Metastatic prostate cancer may pose as upper tract urothelial carcinoma. Prostate may look normal on clinic-radiological examination in prostate cancer. Majority of such cases are managed with nephroureterectomy. Herein, we report a case of 62-year gentleman, who presented with refractory left flank pain with repeated imaging suggestive of neoplastic left ureteric stricture and normal prostate on clinic-radiological examinations. The case was later found with the diagnosis of metastatic prostate adenocarcinoma with neuroendocrine differentiation after left sided nephroureterectomy done for a provisional diagnosis of Upper Tract Urothelial Carcinoma (UTUC).

Download Full-text

Cerebrospinal Fluid Rhinorrhea as the First Symptom of Metastatic Prostate Adenocarcinoma

Ear Nose & Throat Journal ◽

10.1177/01455613211016710 ◽

2021 ◽

pp. 014556132110167

Author(s):

Magdalena Ostrowska ◽

Maciej J. Wróbel

Keyword(s):

Prostate Cancer ◽

Cerebrospinal Fluid ◽

Paranasal Sinuses ◽

Cancer Metastasis ◽

Treatment Strategies ◽

Prostate Adenocarcinoma ◽

Cerebrospinal Fluid Rhinorrhea ◽

Csf Leakage ◽

Prostate Cancer Metastasis ◽

Csf Rhinorrhoea

The most common cause of cerebrospinal fluid (CSF) rhinorrhoea is damage to the skull base with a dura mater’s rupture due to an accident or an iatrogenic injury. This applies to over 96% of cases. Other possibilities that can lead to CSF leakage are neoplasms of the nasal cavity, paranasal sinuses, and nasopharynx. Although prostate cancer spreads to bones, cranial metastases to paranasal sinuses are extremely rare. We present a case of an 83-year-old patient with CSF leakage due to infiltrating metastatic prostate cancer. Cerebrospinal fluid rhinorrhea turned out to be the first symptom of prostate cancer metastasis. Diagnostic and treatment strategies are presented in the discussion.

Download Full-text

Doublecortin expression in prostate adenocarcinoma and neuroendocrine tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.6_suppl.161 ◽

2020 ◽

Vol 38 (6_suppl) ◽

pp. 161-161

Author(s):

Shervin Tabrizi ◽

Mohammed Alshalalfa ◽

Brandon Arvin Virgil Mahal ◽

Elai Davicioni ◽

Yang Liu ◽

...

Keyword(s):

Prostate Cancer ◽

Mouse Models ◽

Neuroendocrine Tumors ◽

De Novo ◽

Strong Association ◽

Prognostic Significance ◽

Xenograft Model ◽

Neuroendocrine Differentiation ◽

Prostate Adenocarcinoma ◽

Normal Prostate

161 Background: Recent work using prostate cancer mouse models implicated doublecortin (DCX)-expressing neural progenitor cells in prostate adenocarcinoma, reporting a strong association between DCX expression and disease progression and outcome. We sought to evaluate the relationship between DCX expression and these outcomes in human prostate cancer. Methods: DCX expression was measured in transcriptome-wide microarray data from 18,501 patients with localized prostate cancer and 290 patients with metastatic castration-resistant prostate cancer (mCRPC). Pairwise comparisons were performed using the Mann–Whitney U test. Metastasis-free survival (MFS) and overall survival (OS) were analyzed using Cox-proportional hazards. Results: DCX expression was not significantly different between normal prostate (n=29), primary prostate cancer (n=131), or metastases (n=19) (p > 0.5), and did not differ across Gleason score in a large cohort of RP samples (n=17,967, p=0.21). The lack of difference persisted after adjusting for stromal contribution using a 141-gene stromal signature. Those with DCX expression above and below the median did not have significant differences in MFS (HR 1.2 [0.84-1.7], p=0.3) or OS (HR 1.15 [0.7-1.84], p =0.56). In a cohort of untreated prostate cancer, DCX expression was higher in neuroendocrine tumors (n=10) compared to Gleason 9-10 prostate adenocarcinoma (n=110) (p=0.007). Similarly, in two cohorts with mCRPC (n=290), DCX expression was higher in lesions with neuroendocrine features than adenocarcinoma (p<0.001). Consistently, in a patient-derived xenograft model subjected to host castration, DCX expression was initially low, but increased significantly once tumors underwent neuroendocrine differentiation and treatment escape. Conclusions: Contrary to recent data using mouse models, DCX expression did not differ by disease state, grade, or outcome in a dataset of human patients with prostate adenocarcinoma. However, DCX expression appeared to correlate with neuroendocrine prostate cancers, a subgroup that can arise de novo or in the castrate-resistant setting. Further work is needed to define the role of DCX expression and its prognostic significance in prostate cancer.

Download Full-text

Prostate Cancer Metastasis Causing Occipital Condyle Syndrome: A Rare Clinical Entity

International Journal Of Medical Science And Clinical Invention ◽

10.18535/ijmsci/v8i03.03 ◽

2021 ◽

Vol 8 (03) ◽

pp. 5272-5274

Author(s):

Nurlan İsayev ◽

Levent Yücel ◽

Hatice Seçil Akyıldız ◽

Hazan Başak ◽

Süha Beton ◽

...

Keyword(s):

Prostate Cancer ◽

Skull Base ◽

Cancer Metastasis ◽

Prostate Adenocarcinoma ◽

Occipital Condyle ◽

Rare Clinical Entity ◽

Resonance Imaging ◽

Case Presentation ◽

Prostate Cancer Metastasis ◽

The Right

Introduction: Prostate cancer metastasis to clivus and occipital condyle are extremely rare and only a few cases are published. We present a case with metastasis of prostate cancer to skull base causing occipital condyle syndrome (OCS). Case Presentation: A-56-year-old man was referred to our clinic with complaints of dysphagia for two months and headache on his right occipital region for five months. There was deviation of the tongue to the right side in his physical examination. He was performed surgery for prostate adenocarcinoma for 2 years ago. Magnetic resonance imaging and computed tomography showed a mass destructed to the clivus and right occipital condyle. Biopsy confirmed the prostate adenocarcinoma metastasis. The patient died after two months from diagnosis of skull base metastasis. Conclusion: Otolaryngologists and urologists should be aware for early diagnosis of OCS in a patient with prostate cancer. Early physical and radiological examination of the patients may improve the prognosis.

Download Full-text

A Unified Transcriptional, Pharmacogenomic, and Gene Dependency Approach to Decipher the Biology, Diagnostic Markers, and Therapeutic Targets Associated with Prostate Cancer Metastasis

Cancers ◽

10.3390/cancers13205158 ◽

2021 ◽

Vol 13 (20) ◽

pp. 5158

Author(s):

Manny D. Bacolod ◽

Francis Barany

Keyword(s):

Prostate Cancer ◽

Cancer Metastasis ◽

Primary Data ◽

Serine Threonine Kinase ◽

Normal Prostate ◽

Response Data ◽

Primary Prostate Cancer ◽

Prostate Cancer Metastasis ◽

Cancer Tissues ◽

Invasive Diagnostics

This manuscript demonstrates how integrated bioinformatic and statistical reanalysis of publicly available genomic datasets can be utilized to identify molecular pathways and biomarkers that may be clinically relevant to metastatic prostate cancer (mPrCa) progression. The most notable observation is that the transition from primary prostate cancer to mPrCa is characterized by upregulation of processes associated with DNA replication, metastasis, and events regulated by the serine/threonine kinase PLK1. Moreover, our analysis also identified over-expressed genes that may be exploited for potential targeted therapeutics and minimally invasive diagnostics and monitoring of mPrCa. The primary data analyzed were two transcriptional datasets for tissues derived from normal prostate, primary prostate cancer, and mPrCa. Also incorporated in the analysis were the transcriptional, gene dependency, and drug response data for hundreds of cell lines, including those derived from prostate cancer tissues.

Download Full-text